Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells (Q44084942)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 June 2013

Language	Label	Description	Also known as
English	Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells	scientific article published on 4 June 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

neoplastic stem cells

1 reference

based on heuristic

inferred from title

Gabriel Capellá

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Mireia M Ginestà

object named as

Mireia M Ginestà

2

0 references

Mariona Graupera

object named as

Mariona Graupera

4

0 references

Oriol Casanovas

object named as

Oriol Casanovas

5

0 references

author name string

Marta Vives

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Kristina Gracova

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Teresa Serrano

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Berta Laquente

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Francesc Viñals

9

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

4 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

133

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

2464-2472

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Pancreatic cancer stem cells - update and future perspectives.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Pancreatic cancer stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Metronomic chemotherapy: an antiangiogenic scheduling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Metronomic chemotherapy: new rationale for new directions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28259

21 January 2018

Identifiers

10.1002/IJC.28259

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44084942&oldid=2106428189"